Works matching IS 22969403 AND DT 2023 AND VI 8 AND IP 2
Results: 7
Front & Back Matter.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 1, doi. 10.1159/000534502
- Publication type:
- Article
Clinical Background Factors as Predictors of the Efficacy of 5-Aminosalicylic Acid Suppositories in Patients with Ulcerative Colitis.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 84, doi. 10.1159/000533543
- By:
- Publication type:
- Article
Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 77, doi. 10.1159/000531654
- By:
- Publication type:
- Article
Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Surrogate Marker of Small Bowel Mucosal Injury in Crohn's Disease.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 69, doi. 10.1159/000531622
- By:
- Publication type:
- Article
Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 91, doi. 10.1159/000531580
- By:
- Publication type:
- Article
Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 60, doi. 10.1159/000531497
- By:
- Publication type:
- Article
Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction.
- Published in:
- Inflammatory Intestinal Diseases, 2023, v. 8, n. 2, p. 51, doi. 10.1159/000531372
- By:
- Publication type:
- Article